Eli Lilly and Company (NYSE:LLY) Issues Earnings Results

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings results on Thursday. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.68 by $1.80, FiscalAI reports. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $7.02 earnings per share.

Here are the key takeaways from Eli Lilly and Company’s conference call:

• Q3 revenue rose 39% to approximately $24 billion, driven by Mounjaro, Zepbound, and broad strength across oncology, immunology, and neuroscience. Lilly raised its 2026 guidance to $91–$92 billion in revenue and $35–$36 in non-GAAP EPS.
• The incretin franchise continued to accelerate, with Mounjaro and Zepbound generating more than $16 billion in combined quarterly revenue. The Medicare GLP-1 Bridge Program has served more than 500,000 prescriptions, with seven in 10 new bridge patients choosing a Lilly obesity medicine.
• Lilly reported encouraging pipeline and regulatory progress, including strong retatrutide results versus semaglutide, positive data for the eloralintide/tirzepatide combination, and U.S. approvals for weekly basal insulin Onswik, expanded pirtobrutinib use, and new tirzepatide and imlunestrant indications.
• Pricing remains a significant headwind, with U.S. realized price declining 10% excluding a favorable rebate adjustment, while expanded Medicare and Medicaid access and self-pay growth are expected to pressure net price per prescription in 2027. Management also cautioned that roughly $2 billion of 2026 one-time benefits will not recur next year.
• Lilly is investing heavily for long-term growth, breaking ground on $11.5 billion of new U.S. manufacturing capacity and adding pipeline assets through the AtaiBeckley and Merida acquisitions, while maintaining a broad set of late-stage programs across oncology, neuroscience, and immunology.

Eli Lilly and Company Stock Up 3.5%

NYSE:LLY traded up $47.91 during midday trading on Friday, reaching $1,421.61. The company had a trading volume of 2,112,087 shares, compared to its average volume of 2,928,289. Eli Lilly and Company has a 12-month low of $834.19 and a 12-month high of $1,449.68. The stock’s fifty day simple moving average is $1,194.34 and its 200-day simple moving average is $1,090.89. The firm has a market capitalization of $1.34 trillion, a price-to-earnings ratio of 47.78, a PEG ratio of 1.73 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted earnings per share of $7.48 exceeded analyst expectations. Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion. Reuters: Eli Lilly lifts revenue outlook
• Positive Sentiment: Mounjaro sales climbed 65% to $10.7 billion and Zepbound sales increased 49% to $5.35 billion. Combined tirzepatide sales surpassed $16 billion, reinforcing Lilly’s leadership in the rapidly expanding GLP-1 diabetes and weight-loss market. Pharmaceutical Technology: Eli Lilly’s tirzepatide outperforms
• Positive Sentiment: Management highlighted expanding Medicare access, rising demand from middle-income consumers and encouraging traction for Foundayo. Positive Phase 3 results for experimental obesity and diabetes drug retatrutide also strengthened expectations for Lilly’s future pipeline and increased competitive pressure on Novo Nordisk. Zacks: LLY Q3 earnings call highlights
• Neutral Sentiment: Lilly’s pipeline is broadening beyond GLP-1 therapies, with cancer, immunology and neuroscience products viewed as potential additional growth drivers. However, the stock’s strong rally has raised the performance bar and leaves investors focused on whether growth can remain strong at its current valuation. Yahoo Finance: Cancer drugs as future growth drivers
• Negative Sentiment: Realized prices fell about 15%, although a 53% volume increase more than offset the decline. Results also benefited from roughly $900 million in favorable items, while acquisition-related charges reduced earnings. Potential employer cutbacks in weight-loss-drug coverage and ongoing pricing pressure remain risks. Motley Fool: Eli Lilly sells more at lower prices

Insiders Place Their Bets

In other news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last quarter. Company insiders own 0.14% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Royal Bank Of Canada lifted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a report on Friday. TD Cowen reiterated a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Sanford C. Bernstein reissued an “outperform” rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a research note on Monday. Bank of America reissued a “buy” rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a research note on Friday. Finally, Leerink Partners lifted their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,374.46.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.